Aspergillosis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aspergillosis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Aspergillosis - Pipeline Review, H2 2015', provides an overview of the Aspergillosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aspergillosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Aspergillosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Aspergillosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Aspergillosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Aspergillosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Aspergillosis Overview 10
Therapeutics Development 11
Pipeline Products for Aspergillosis - Overview 11
Pipeline Products for Aspergillosis - Comparative Analysis 12
Aspergillosis - Therapeutics under Development by Companies 13
Aspergillosis - Therapeutics under Investigation by Universities/Institutes 15
Aspergillosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Aspergillosis - Products under Development by Companies 20
Aspergillosis - Products under Investigation by Universities/Institutes 21
Aspergillosis - Companies Involved in Therapeutics Development 22
Amplyx Pharmaceuticals, Inc. 22
Astellas Pharma Inc. 23
Aureogen Biosciences, Inc. 24
Biomar Microbial Technologies 25
Cidara Therapeutics, Inc. 26
Eisai Co., Ltd. 27
F2G Ltd 28
Globavir Biosciences, Inc. 29
Hsiri Therapeutics, LLC 30
iCo Therapeutics Inc. 31
Merck & Co., Inc. 32
Nanomerics Ltd 33
Novabiotics Limited 34
Pulmocide Ltd 35
Scynexis, Inc. 36
Sealife PHARMA GMBH 37
Sigma-Tau S.p.A. 38
TGV-Laboratories 39
Vical Incorporated 40
Aspergillosis - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
amphotericin b - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
amphotericin B - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
amphotericin B - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
amphotericin b NanoDisk - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
APX-001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ASP-9726 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Aspergillus fumigatus vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AUGC-10 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AUGC-15 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
C-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
C-016 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
E-1210 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
F-901318 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GBV-006 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
KB-425796C - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MDN-0018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Myc-102 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NP-339 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NP-525 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
posaconazole - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PTX-3 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SCY-078 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SLP-0901 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SLP-0904 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule for Aspergillosis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Fungal Infections - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for Fungal Infections - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Invasive Pulmonary Aspergillosis - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Inhibit ABC Transporter for Fungal Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
VL-2397 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Aspergillosis - Recent Pipeline Updates 83
Aspergillosis - Dormant Projects 89
Aspergillosis - Discontinued Products 90
Aspergillosis - Product Development Milestones 91
Featured News & Press Releases 91
Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 91
Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 91
Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate 92
Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas 92
Jan 09, 2015: SCYNEXIS Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 93
Sep 09, 2014: F2G Announces A Major Funding Award From The Technology Strategy Board`s Biomedical Catalyst 94
Sep 02, 2014: F2G announces commencement of a Phase 1 single ascending dose study of a novel antifungal agent, F901318 94
Jul 30, 2014: CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Merck's NOXAFIL (posaconazole) 95
Mar 17, 2014: Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL Injection for Intravenous Use, a New Captisol-enabled Formulation 95
Mar 14, 2014: FDA Approves Merck's NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables

Number of Products under Development for Aspergillosis, H2 2015 11
Number of Products under Development for Aspergillosis - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Investigation by Universities/Institutes, H2 2015 21
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015 22
Aspergillosis - Pipeline by Astellas Pharma Inc., H2 2015 23
Aspergillosis - Pipeline by Aureogen Biosciences, Inc., H2 2015 24
Aspergillosis - Pipeline by Biomar Microbial Technologies, H2 2015 25
Aspergillosis - Pipeline by Cidara Therapeutics, Inc., H2 2015 26
Aspergillosis - Pipeline by Eisai Co., Ltd., H2 2015 27
Aspergillosis - Pipeline by F2G Ltd, H2 2015 28
Aspergillosis - Pipeline by Globavir Biosciences, Inc., H2 2015 29
Aspergillosis - Pipeline by Hsiri Therapeutics, LLC, H2 2015 30
Aspergillosis - Pipeline by iCo Therapeutics Inc., H2 2015 31
Aspergillosis - Pipeline by Merck & Co., Inc., H2 2015 32
Aspergillosis - Pipeline by Nanomerics Ltd, H2 2015 33
Aspergillosis - Pipeline by Novabiotics Limited, H2 2015 34
Aspergillosis - Pipeline by Pulmocide Ltd, H2 2015 35
Aspergillosis - Pipeline by Scynexis, Inc., H2 2015 36
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2015 37
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H2 2015 38
Aspergillosis - Pipeline by TGV-Laboratories, H2 2015 39
Aspergillosis - Pipeline by Vical Incorporated, H2 2015 40
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 45
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Aspergillosis Therapeutics - Recent Pipeline Updates, H2 2015 83
Aspergillosis - Dormant Projects, H2 2015 89
Aspergillosis - Discontinued Products, H2 2015 90